The
GE Discovery MI Gen 2 is a next-generation
hybrid PET/CT platform that redefines molecular imaging through its fully
digital PET detector technology, high-performance
CT subsystem, and intelligent
quantitative software suite. Designed for
oncology, cardiology, and neurology, it delivers
unmatched sensitivity,
ultra-high spatial resolution, and
significantly reduced radiation exposure—enabling earlier diagnosis, precise therapy monitoring, and personalized care.
Available in
three scalable configurations, the system offers flexible clinical deployment:
- Discovery MI 3R: 15 cm axial field of view (AFOV) — ideal for routine oncology and focused studies
- Discovery MI 4R: 20 cm AFOV — balanced performance for comprehensive whole-body and organ-specific imaging
- Discovery MI 5R: 25 cm AFOV — the longest digital PET coverage available, enabling whole-body PET acquisition in a single bed position with exceptional speed and sensitivity
This scalability allows institutions to select the optimal configuration based on patient volume, clinical focus, and research ambitions—without compromising on image quality or quantitative accuracy.
Powered by
silicon photomultipliers (SiPM) and
lutetium-based scintillators (LBS), the Discovery MI Gen 2 achieves a
TOF resolution of 385 picoseconds and a
record NEMA sensitivity of up to 21 kcps/MBq/mL (5R)—the highest among all commercial TOF-PET/CT systems. Combined with
Q.Clear advanced reconstruction and low-dose CT, it ensures diagnostic confidence even at ultra-low radiotracer doses or ultrafast scan times.
With seamless integration into clinical workflows, cloud-ready analytics, and support for quantitative biomarkers, the
Discovery MI Gen 2 represents the future of precision molecular imaging—delivering speed, sensitivity, and scientific rigor across the full spectrum of modern medicine.